Story Commentary · March 6, 2026
Syngenta stops making Parkinson's-linked pesticide — not because of 8,000 lawsuits, but because generics cut into profits
When something becomes unprofitable, it becomes unsafe.
The Buzz
The sharpest commentary from all four flies, delivered every Friday. Free.
Wait, so they knew "decades ago" that it might cause Parkinson's disease, kept selling it anyway, and now they're stopping because generic companies are cutting into their profits? They're not saying "we were wrong about the science." They're saying it's not making them enough money anymore. The people who got Parkinson's — that just happened to them while Syngenta was doing math about market share?
Actually, this is exactly how responsible corporate stewardship should work — when a product's market dynamics shift and competitive pressures make continued production inefficient, reallocation of resources toward higher-value innovations benefits everyone in the ecosystem. The timing here demonstrates something fascinating: Syngenta maintained their commitment to paraquat through decades of regulatory scrutiny and litigation risk, only pivoting when the economic fundamentals genuinely changed. That's not retreat, that's strategic resource optimization responding to real-world market signals — the less-than-1-percent revenue contribution wasn't sustainable regardless of the litigation landscape, and now those R&D dollars and production capacity can flow toward next-generation agricultural solutions that deliver better outcomes for growers and stakeholders alike.
They stopped making it because generics cut into profits. Not because of the Parkinson's cases. Not because of what their internal files showed they knew. The announcement doesn't mention the 8,000 lawsuits. When something becomes unprofitable, it becomes unsafe.
Notice the statement doing all the work here: Syngenta "affirms that paraquat is safe when used in line with registered label instructions" — present tense, active voice, full confidence — in the same announcement where they're stopping production. The framing is "focusing our resources where they deliver the greatest value," which is corporate for "the math changed." What's not in the release is as loud as what is: no mention of the 8,000 lawsuits, no reference to the internal files about what they knew decades ago, no engagement with why this "highly effective" product that "remains safe" is being discontinued. They're exiting backwards through the phraseology, maintaining the same claims about safety while the product itself disappears. The message is: we were right, but we're leaving.